Your browser doesn't support javascript.
loading
Post-trial access in implanted neural device research: Device maintenance, abandonment, and cost.
Lázaro-Muñoz, Gabriel; Pham, Michelle T; Muñoz, Katrina A; Kostick-Quenet, Kristin; Sanchez, Clarissa E; Torgerson, Laura; Robinson, Jill; Pereira, Stacey; Outram, Simon; Koenig, Barbara A; Starr, Philip A; Gunduz, Aysegul; Foote, Kelly D; Okun, Michael S; Goodman, Wayne; McGuire, Amy L; Zuk, Peter.
Afiliación
  • Lázaro-Muñoz G; Center for Bioethics, Harvard Medical School, 641 Huntington Avenue, Boston, MA, 02115, United States; Department of Psychiatry, Massachusetts General Hospital, 55 Fruit Street, Boston, MA, 02114, United States. Electronic address: glazaro@hms.harvard.edu.
  • Pham MT; Center for Bioethcis and Social Justice, College of Human Medicine, Michigan State University, East Fee Hall 965 Wilson Road Rm A-126, East Lansing, MI, 48824, United States.
  • Muñoz KA; Center for Medical Ethics and Health Policy, Baylor College of Medicine, One Baylor Plaza, Suite 326D, Houston, TX, 77030, United States.
  • Kostick-Quenet K; Center for Medical Ethics and Health Policy, Baylor College of Medicine, One Baylor Plaza, Suite 326D, Houston, TX, 77030, United States.
  • Sanchez CE; Center for Medical Ethics and Health Policy, Baylor College of Medicine, One Baylor Plaza, Suite 326D, Houston, TX, 77030, United States.
  • Torgerson L; Center for Medical Ethics and Health Policy, Baylor College of Medicine, One Baylor Plaza, Suite 326D, Houston, TX, 77030, United States.
  • Robinson J; Center for Medical Ethics and Health Policy, Baylor College of Medicine, One Baylor Plaza, Suite 326D, Houston, TX, 77030, United States.
  • Pereira S; Center for Medical Ethics and Health Policy, Baylor College of Medicine, One Baylor Plaza, Suite 326D, Houston, TX, 77030, United States.
  • Outram S; Program in Bioethics, University of California, 490 Illinois Street, San Francisco, CA, 94143, United States.
  • Koenig BA; Program in Bioethics, University of California, 490 Illinois Street, San Francisco, CA, 94143, United States.
  • Starr PA; Department of Neurological Surgery, University of California, 400 Parnassus Avenue, San Francisco, CA, 94143, United States.
  • Gunduz A; Norman Fixel Institute for Neurological Diseases, Departments of Neurology and Neurosurgery, University of Florida, 3009 SW Williston Road, Gainesville, FL, 32608, United States; Department of Biomedical Engineering, University of Florida, 1275 Center Drive, Biomedical Science Building, JG56, Gaines
  • Foote KD; Norman Fixel Institute for Neurological Diseases, Departments of Neurology and Neurosurgery, University of Florida, 3009 SW Williston Road, Gainesville, FL, 32608, United States.
  • Okun MS; Norman Fixel Institute for Neurological Diseases, Departments of Neurology and Neurosurgery, University of Florida, 3009 SW Williston Road, Gainesville, FL, 32608, United States.
  • Goodman W; Department of Psychiatry and Behavioral Sciences, Baylor College of Medicine, 1977 Butler Blvd Suite E4.100, Houston, TX, 77030, United States.
  • McGuire AL; Center for Medical Ethics and Health Policy, Baylor College of Medicine, One Baylor Plaza, Suite 326D, Houston, TX, 77030, United States.
  • Zuk P; Center for Bioethics, Harvard Medical School, 641 Huntington Avenue, Boston, MA, 02115, United States.
Brain Stimul ; 15(5): 1029-1036, 2022.
Article en En | MEDLINE | ID: mdl-35926784
ABSTRACT

BACKGROUND:

Clinical trial participants who benefit from experimental neural devices for the treatment of debilitating and otherwise treatment-resistant conditions are generally not ensured continued access to effective therapy or maintenance of devices at the conclusion of trials. OBJECTIVE/

HYPOTHESIS:

Post-trial obligations have been extensively examined in the context of drug trials, but there has been little empirical examination of stakeholder perspectives regarding these obligations in the rapidly growing field of neural device research.

METHODS:

This study examined the perspectives of 44 stakeholders (i.e., 23 researchers and 21 patient-participants) involved in implantable neural device trials.

RESULTS:

Researchers were concerned about current post-trial management, identified barriers like cost, and suggested ways to improve the system. Many patient-participants were unaware of whether they would have post-trial access, but most thought they should keep devices if beneficial, and agreed with researchers that more should be done to help them keep and maintain these neural devices.

CONCLUSION:

To our knowledge, this is the first in-depth examination of researcher perspectives regarding continued access to experimental neural devices and only the second such examination of patient-participant perspectives. These data can help inform future ethical and policy decisions about post-trial access to implantable neurotechnology.
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Contexto en salud: 1_ASSA2030 Problema de salud: 1_financiamento_saude Tipo de estudio: Health_economic_evaluation / Prognostic_studies Aspecto: Ethics Idioma: En Revista: Brain Stimul Asunto de la revista: CEREBRO Año: 2022 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Contexto en salud: 1_ASSA2030 Problema de salud: 1_financiamento_saude Tipo de estudio: Health_economic_evaluation / Prognostic_studies Aspecto: Ethics Idioma: En Revista: Brain Stimul Asunto de la revista: CEREBRO Año: 2022 Tipo del documento: Article
...